Biosimilars in oncology: from development to clinical practice.

Area of Science:

• Oncology
• Pharmacoeconomics
• Regulatory Science

Background:

• Biologics are crucial in cancer treatment but are costly, straining healthcare systems.
• Biosimilars, highly similar to branded biologics, offer potential cost savings.
• Patent expirations of key biologics create opportunities for biosimilar adoption.

Purpose of the Study:

• To review critical factors for integrating biosimilars into oncology.
• To address clinician needs for evaluating biosimilar efficacy, safety, and interchangeability.
• To discuss evolving regulatory and educational considerations for biosimilar acceptance.

Main Methods:

• Literature review of biologics and biosimilars in oncology.
• Analysis of regulatory pathways and clinical development strategies.
• Examination of factors influencing clinical practice integration and decision-making.

Main Results:

• Biosimilars can increase access to cancer care and reduce costs.
• Regulatory frameworks and standardization efforts for biosimilars are developing.
• Key considerations include efficacy, safety, interchangeability, and pharmacovigilance.

Conclusions:

• Biosimilar integration requires education for healthcare providers, payers, and patients.
• Informed decision-making can facilitate biosimilar acceptance and associated benefits.
• Evolving guidelines and standardization will support robust clinical development and use.